SC&H Financial Advisors Inc. Has $669,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

SC&H Financial Advisors Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 12.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,768 shares of the company’s stock after purchasing an additional 411 shares during the quarter. SC&H Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $669,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. DORCHESTER WEALTH MANAGEMENT Co raised its stake in shares of Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its stake in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the last quarter. IFM Investors Pty Ltd raised its stake in shares of Johnson & Johnson by 20.1% in the first quarter. IFM Investors Pty Ltd now owns 418,999 shares of the company’s stock valued at $74,259,000 after acquiring an additional 70,221 shares during the last quarter. Essex LLC raised its position in Johnson & Johnson by 3.7% in the 1st quarter. Essex LLC now owns 32,274 shares of the company’s stock worth $5,720,000 after purchasing an additional 1,146 shares during the last quarter. Finally, Hardy Reed LLC raised its position in Johnson & Johnson by 2.7% in the 1st quarter. Hardy Reed LLC now owns 5,098 shares of the company’s stock worth $904,000 after purchasing an additional 133 shares during the last quarter. 68.59% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $176.20 on Monday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The firm has a market capitalization of $460.67 billion, a price-to-earnings ratio of 24.54, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a fifty day moving average of $167.84 and a 200-day moving average of $171.29.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the previous year, the business earned $2.60 EPS. The firm’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its Board of Directors has approved a stock repurchase program on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Insider Activity

In related news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The disclosure for this sale can be found here. Insiders sold 118,795 shares of company stock valued at $20,230,174 in the last quarter. Company insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. Raymond James dropped their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Credit Suisse Group began coverage on shares of Johnson & Johnson in a research report on Thursday. They issued a “neutral” rating and a $170.00 price objective for the company. Barclays initiated coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective for the company. Finally, Bank of America lowered their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $181.33.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.